BridgeBio Reports Strong Q4/FY25 Results, Multiple Phase 3 Successes, and Key NDA Submissions

summarizeSummary

BridgeBio Pharma announced its fourth quarter and full year 2025 financial results, highlighted by significant revenue growth from Attruby and positive Phase 3 readouts for three key pipeline assets, positioning the company for multiple NDA submissions in 2026.

check_boxKey Events

• Strong Commercial Growth for Attruby

  Attruby generated $146.0 million in net product revenue for Q4 2025, contributing to $362.4 million for the full year, demonstrating 35% quarter-over-quarter growth and reaching 7,804 unique patient prescriptions.

• Three Positive Phase 3 Trial Readouts

  The company reported successful Phase 3 results for PROPEL 3 (infigratinib for achondroplasia), FORTIFY (BBP-418 for LGMD2I/R9), and CALIBRATE (encaleret for ADH1), marking significant clinical advancements across its pipeline.

• Multiple NDA Submissions Planned for 2026

  BridgeBio is on track to submit NDAs to the FDA for BBP-418 and encaleret in 1H 2026, and for infigratinib in 2H 2026, with potential U.S. launches anticipated in late 2026/early 2027.

• Solid Financial Position and Recent Financing

  The company ended 2025 with $587.5 million in cash, cash equivalents, and marketable securities, further bolstered by the issuance of $632.5 million in convertible notes in January 2026, positioning it to fund planned operations.

auto_awesomeAnalysis

BridgeBio Pharma's latest 8-K filing details robust commercial performance for Attruby, alongside a series of highly positive clinical milestones. The successful Phase 3 readouts for infigratinib, BBP-418, and encaleret significantly de-risk the pipeline and set the stage for multiple New Drug Application (NDA) submissions in 2026. This strong execution on both commercial and development fronts provides a clear path to potential new product launches and revenue streams, reinforcing the company's growth trajectory in genetic conditions.